Tirzepatide Once Weekly for the Treatment of Obesity

Тирзепатид один раз в неделю для лечения ожирения
Bing Liu, Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, Sean Wharton, Lisa E. Connery, Breno Edson Sendão Alves, Arihiro Kiyosue, Shuyu Zhang, Mathijs C. Bunck, Adam Stefański, Mathijs C. M. Bunck, Breno Alves
2022-06-04

GIP receptor agonistGLP-1 receptor agonistObesity treatmentRandomized controlled trialTirzepatide
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
1
All prespecified cardiometabolic measures improved with tirzepatide treatment, according to the abstract.
2
At least 5% weight loss occurred in 85%, 89%, and 91% of participants receiving 5, 10, and 15 mg tirzepatide, respectively, compared with 35% receiving placebo.
3
In a 72-week phase 3 trial of 2539 adults with obesity without diabetes, weekly tirzepatide produced substantially greater weight loss than placebo.
4
Mean weight change was -15.0%, -19.5%, and -20.9% with tirzepatide doses of 5, 10, and 15 mg, respectively, versus -3.1% with placebo.
5
Weight loss of at least 20% occurred in 50% of participants receiving 10 mg and 57% receiving 15 mg tirzepatide, versus 3% with placebo.

Adults with obesity or overweight and weight-related complications, excluding diabetes, treated with once-weekly subcutaneous tirzepatide

The efficacy and safety of once-weekly tirzepatide for weight reduction and cardiometabolic improvement

Publication Details
Publication Date
2022-06-04
Journal
Publisher
ISSN
Cited by
4076
Access Type
Author Information
Authors
Bing Liu
Ania M. Jastreboff
Louis J. Aronne
Nadia N. Ahmad
Sean Wharton
Lisa E. Connery
Breno Edson Sendão Alves
Arihiro Kiyosue
Shuyu Zhang
Mathijs C. Bunck
Adam Stefański
Mathijs C. M. Bunck
Breno Alves
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%